Millennium Reports Velcade Results

Millennium presented interim results from the first 256 multiple myeloma patients in its Phase III trial of Velcade.

The study compared Velcade, thalidomide and dexamethasone (VcTD) with thalidomide and dexamethasone (TD) alone — the standard therapy for patients with previously untreated multiple myeloma.

Prior to transplantation, 36 percent of subjects in the VcTD arm achieved complete remission compared with 9 percent in the TD arm. Following transplantation, 57 percent of VcTD subjects compared with 28 percent of TD subjects achieved complete remission, Millennium said.